| 영문 | dopamine | 한글 | 도파민 |
|---|---|---|---|
| 설명 | 히드록시티라민으로서 생리활성 아민-카테콜아민의 일종. 분자식은C18H11NO2, 분자량은 153.18이다. 동식물에 존재하는 아미노산의 하나로, 자외선 작용으로 티로신에서 형성되거나 L-Dopa의 탈탄산에 의해 체내에서 생산된다. 멜라닌 색소 합성 과정의 중간 물질로 콩과 식물에 저장되어 있다. 뇌신경 세포의 흥분 전달에 중요한 구실을 한다. 도파민β-산화효소의 작용에 의해 노르아드레날린이 된다. 부신수질-뇌-교감신경계-폐-작은창자-간 등에도 많이 포함되어 있다. 파킨슨 증후군의 경우 뇌 안의 도파민 량이 감소되며, 뇌줄기의 줄무늬체에는 노르아드레날린보다 도파민이 다량 포함되어 있음을 볼 수 있다는 점에서 도파민 자체가 이른바 카테콜아민을 함유하는 작동성 뉴런의 신경전달물질로서 작용하고 있음이 분명해졌다. |
||
| DOPA | 3,4-Dihydr-Oxy-Phenyl-Alanine |
|---|---|
| DOPA, dopa | dihydroxyphenylalanine |
| DOPAC | dihydrophenylacetic acid |
| DOPAMINE | dihydroxyphenylethylamine |
| dopase | dihydroxyphenylalanine oxidase |
| L-DOPA, | L-dopa levodopa, levo-3, 4-dihydroxyphenylalanine |
|---|---|
| DDC | L-Dopa De-Carboxylase |
| DOPA | 3,4-dihydrophenylalanine |
|---|---|
| DOPA | dioleolylphosphatidic acid |
| DOPAC | dihydrophenylacetic acid |
| DOPAL | 3,4-Dihydroxyphenylacetaldehyde |
| dopamine | 3,4-Dihydroxyphenylethylamine |
| (18)F-DOPA | 6-[(18)F]fluoro-L-DOPA |
|---|---|
| L-DOPA | L-Dihydroxphenylalanine |
| 6-FD | 18F]6-fluoro-L-dopa |
| DA | DOPA and dopamine |
| DDC | DOPA decarboxylase |
| dopa | An amino acid derived from the amino acid tyrosine. It is formed as the first intermediate in the production of dopamine, a neurotransmitter. (09 Oct 1997) |
|---|---|
| dopa decarboxylase | <enzyme> One of the aromatic-l-amino-acid decarboxylases, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of parkinson's disease. Registry number: EC 4.1.1.- (12 Dec 1998) |
| DOPA dioxygenase | <enzyme> Key enzyme in betalain biosynthesis pathway of amanita muscaria; genbank y12886 Registry number: EC 1.14.99.- Synonym: dopa-4,5-dioxygenase, doda gene product (26 Jun 1999) |
| dopa oxidase | Provisional name given the enzyme(s) catalyzing the formation of melanins from dopa; it now appears that the copper-containing monophenol monooxygenases and/or catechol oxidases are responsible for the oxidation of l-tyrosine to dopa and dopa quinone. (05 Mar 2000) |
| dopa quinone | An oxidation product of dopa and an intermediate in the formation of melanin from tyrosine. (05 Mar 2000) |
| dopa reaction | A dark staining observed in fresh tissue sections to which a solution of dopa has been applied, presumably due to the presence of dopa oxidase in the protoplasm of certain cells. Synonym: Bloch's reaction. (05 Mar 2000) |
| dopa-responsive dystonia | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| Dopa-tyrosine sulfotransferase | <enzyme> Active towards tyrosine and dopa isomers except dl-ortho-tyrosine; isolated from rat liver; genbank u38419 Registry number: EC 2.8.2.- (26 Jun 1999) |
| dopachrome oxidoreductase | <enzyme> Decarboxylates and converts dopachrome to 5,6-dihydroxyindole; does not convert the latter to indole-5,6-quinone; found in human and mouse hairbulbs; proposed EC 5.3.2.3 Registry number: EC 5.3.2.- Synonym: dopachrome conversion factor, indole blocking factor, dopachrome tautomerase, tyrosinase-related protein-2, trp-2, dopachrome isomerase, dopachrome conversion enzyme (26 Jun 1999) |
| dopamine | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopamine agents | Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (12 Dec 1998) |
| dopamine agonists | Drugs that bind to and activate dopamine receptors. (12 Dec 1998) |
| dopamine antagonists | Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of tourette syndrome, and for hiccup. (12 Dec 1998) |
| dopamine beta-hydroxylase | <enzyme> Chemical name: 3,4-Dihydroxyphenethylamine, ascorbate:oxygen oxidoreductase (beta-hydroxylating) Registry number: EC 1.14.17.1 (12 Dec 1998) |
| dopamine beta-monooxygenase | A copper-containing enzyme catalyzing oxidation of ascorbate and 3,4-dihydroxyphenylethylamine simultaneously by O2 to yield norepinephrine, dehydroascorbate, and water; a crucial step in catecholamine metabolism. Synonym: dopamine beta-hydroxylase. (05 Mar 2000) |
| alpha methyl dopa | <drug> An antihypertensive drug, preferred in pregnant patients. (18 Nov 1997) |
|---|---|
| decarboxylated dopa | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dystonia, dopa-responsive | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| l-dopa | <chemical> The naturally occurring form of dopa and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonism and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Pharmacological action: antiparkinson agents, dopamine agents. (12 Dec 1998) |
| L-dopa peroxidase | <enzyme> Found in human erythrocytes associated with catalase Registry number: EC 1.11.- (26 Jun 1999) |
Synonyms : Decarboxylase, Dopa
Synonyms : 3, 4-Dihydroxyphenethylamine, 4-(2-Aminoethyl)-1, 2-benzenediol, Dopamine Hydrochloride, Intropin, 3, 4 Dihydroxyphenethylamine, Hydrochloride, Dopamine
Synonyms : Dopamine Drugs, Dopaminergic Agents, Dopaminergic Drugs, Agents, Dopamine, Agents, Dopaminergic, Drugs, Dopamine, Drugs, Dopaminergic
Synonyms : Agonists, Dopamine Receptor, Agonists, Dopaminergic, Dopamine Agonist, Dopamine Receptor Agonist, Dopaminergic Agonist, Receptor Agonists, Dopamine, Agonist, Dopamine, Agonist, Dopamine Receptor, Agonist, Dopaminergic, Agonists, Dopamine
Synonyms : DARPP-32 Protein, Dopamine and Adenosine 3', 5'-Monophosphate-Regulated Phosphoprotein, Dopamine and cAMP-Regulated Phosphoprotein, Dopamine- and Cyclic AMP-Regulated Phosphoprotein Mr 32, 000, DARPP 32 Protein, Dopamine and cAMP Regulated Phosphoprotein
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
명문이노판주사 - 새창
|
명문제약 |
A31800721 | Dopamine HCl | 전문의약품 | 급여 | 분업예외의약품 |
|
태평양도파민주사액 - 새창
|
태평양제약 |
A02302871 | Dopamine HCl | 전문의약품 | 삭제 | 분업예외의약품 |
|
유도파주 - 새창
|
한국유나이티드제약 |
A12900401 | Dopamine HCl | 전문의약품 | 급여 | 분업예외의약품 |
|
도프라민주 - 새창
|
이연제약 |
A01400681 | Dopamine HCl | 전문의약품 | 급여 |
|
도파신주사 - 새창
|
하나제약 |
A20450351 | Dopamine HCl | 전문의약품 | 급여 | 분업예외의약품 |
|
트로핀주200mg - 새창
|
한림제약 |
A37800471 | Dopamine HCl | 전문의약품 | 급여 | 분업예외의약품 |
|
동국염산도파민주사200mg(프리필드) - 새창
|
동국제약 |
A00701121 | Dopamine HCl | 전문의약품 | 급여 |
|
동국염산도파민주사400mg(프리필드) - 새창
|
동국제약 |
A00701391 | Dopamine HCl | 전문의약품 | 급여 |
|
도푸라민주50mg - 새창
|
이연제약 |
A01401631 | Dopamine HCl | 전문의약품 | 삭제 | 분업예외의약품 |
|
트로핀주 - 새창
|
한림제약 |
A37800301 | Dopamine HCl | 전문의약품 | 급여 | 분업예외의약품 |
| dopa |
amino acid that is formed in the liver and converted into dopamine in the brain
출처: wordnet.princeton.edu/perl/webwn
|
|---|---|
| dopamine |
a monoamine neurotransmitter found in the brain and essential for the normal functioning of the central nervous system; as a drug (trade names Dopastat and Intropin) it is used to treat shock and hypotension
출처: wordnet.princeton.edu/perl/webwn
|
| dopamine |
A neurotransmitter that transmits impulses between neurons within the brain.
출처: www.geocities.com/templarser/complexglos.html
|
| dopamine |
A neurotransmitter that controls movement and balance and is essential to the proper functioning of the central nervous system (CNS). Dopamine assists in the effective transmission of electrochemical signals from one nerve cell (neuron) to another.
출처: www.dbs-stn.org/glossary1.asp
|
| dopant |
an Impurity added to a semiconductor to change the number of holes and electrons relative to each other.
출처: www.icknowledge.com/glossary/d.html
|
| dopa | amino acid that is formed in the liver and converted into dopamine in the brain |
|---|---|
| dopa | a monoamine neurotransmitter found in the brain and essential for the normal functioning of the central nervous system |
| dopa | a monoamine neurotransmitter found in the brain and essential for the normal functioning of the central nervous system |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
